<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157804</url>
  </required_header>
  <id_info>
    <org_study_id>2011-006100-12</org_study_id>
    <nct_id>NCT03157804</nct_id>
  </id_info>
  <brief_title>Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A</brief_title>
  <acronym>FANCOLEN-1</acronym>
  <official_title>Clinical Trial Phase I / II to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34 + Cells Transduced With a Lentiviral Vector Carrying the Gene FANCA in Patients With FA Subtype A (FANCOLEN-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación en Red de Enfermedades Raras (CIBERER)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitat Autonoma de Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</source>
  <brief_summary>
    <textblock>
      This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a
      hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector
      carrying the FANCA gene for patients with Fanconi Anemia of Subtype A .

      CD34 + cells derived from bone marrow and / or mobilized peripheral blood (fresh and / or
      cryopreserved) from patients with Fanconi subtype A (FA-A), will be transduced ex vivo with a
      lentiviral vector carrying the gene FANCA (orphan drug) . After transduction the cells will
      be inoculated in patients in order to restore their hematopoiesis with genetically corrected
      stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this open-label Phase I / II clinical trial is to evaluate the safety
      and therapeutic efficacy of a hematopoietic gene therapy procedure with an orphan drug
      consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi's Anemia
      Subtype A.

      The drug to be administered to the patients consists of the cellular product resulting from
      the transduction of autologous CD34 + cells with the therapeutic lentiviral vector
      PGK-FANCA.Wpre *.

      The dose of cells to infuse in the patients will be that obtained from the transduction
      process of between 3x10^5 and 4x10^6 CD34 + cells / kg of patient body weight.

      The cells will be infused intravenously in a single dose, after complete the transduction
      process.

      Follow-up period: 2 years after infusion of transduced cells. However, patients will be
      monitored outside the clinical trial over a 10-year period.

      Follow-up of the grafted transduced cells will be performed on peripheral blood and bone
      marrow samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 2 years after infusion of transduced cells</time_frame>
    <description>All adverse events will be registered for 2 years from infusion of transduced cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells two years after infusion.</measure>
    <time_frame>2 years after infusion of transduced cells</time_frame>
    <description>Detection of at least 0.1 copy of the therapeutic vector per nucleated bone marrow cell or peripheral blood cells two years after infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector</measure>
    <time_frame>2 years after infusion of transduced cells</time_frame>
    <description>Proportion of patients with clinical hematological response (improvement of cell blood counts at least in one hematological lineage).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)</intervention_name>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Genetically Engineered Hematopoietic Stem/Progenitor Cells</intervention_name>
    <description>Undergo infusion of genetically modified hematopoietic progenitor cell therapy</description>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
    <other_name>Genetically Engineered HSPCs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given subcutaneously (SC)</description>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
    <other_name>Filgrastim XM02, Filgrastim-sndz, G-CSF (Colony Stimulating Factor), Neupogen, r-metHug-CSF, Recombinant Methionyl Human Granulocyte CSF, rG-CSF, Tbo-filgrastim, Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
    <other_name>AMD 3100, JM-3100, Mozobil, SDZ SID 791</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Aspiration</intervention_name>
    <arm_group_label>Autologous CD34+ cells transducted with PGK-FANCA-Wpre *</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Fanconi Anemia complementation group A (FA-A)

          -  At least one of the following parameters should be lower than the indicated values:
             Hemoglobin: 8.0 g / dL; Number of neutrophils: 1,000 / mm^3; Number of platelets:
             50,000 / mm^3

          -  Minimum age 1 year

          -  Maximum age 21 years

          -  Lansky Index&gt; 60%.

          -  Informed consent in accordance with current legal regulations.

          -  Number of cells to be transduced: At least 3x10^5 purified CD34+ / kg body weight.

          -  Negative result in the urine pregnancy test at the baseline visit for women of
             childbearing age, who should be committed to using an effective contraceptive method
             during the period of study participation.

        Exclusion Criteria:

          -  Patients with an human leukocyte antigen (HLA) identical family donor.

          -  Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities
             predicting the same in bone marrow aspirates. In this case, the studies carried out
             two months in advance of the patient's entry into the clinical trial will be
             considered valid.

          -  Evidence that the patient to be infused has signs of somatic mosaicism, with
             hematologic improvement.

          -  Any illness or concomitant process that in the opinion of the investigator
             incapacitates the subject for their participation in the study.

          -  Pre-existing sensory or motor impairment&gt; = grade 2 according to the National Cancer
             Institute (NCl) criteria.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan A Bueren</last_name>
    <role>Study Director</role>
    <affiliation>CIEMAT/CIBERER/IIS.FJD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julian Sevilla</last_name>
    <phone>+34 915035938</phone>
    <email>julian.sevilla@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Diaz de Heredia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil del Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Sevilla</last_name>
      <phone>915035938</phone>
      <email>julian.sevilla@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Adair JE, Sevilla J, Heredia CD, Becker PS, Kiem HP, Bueren J. Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Curr Gene Ther. 2017;16(5):338-348. doi: 10.2174/1566523217666170119113029.</citation>
    <PMID>28103787</PMID>
  </reference>
  <reference>
    <citation>Molina-Estevez FJ, Nowrouzi A, Lozano ML, Galy A, Charrier S, von Kalle C, Guenechea G, Bueren JA, Schmidt M. Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. Curr Gene Ther. 2015;15(6):550-62.</citation>
    <PMID>26415575</PMID>
  </reference>
  <reference>
    <citation>González-Murillo A, Lozano ML, Alvarez L, Jacome A, Almarza E, Navarro S, Segovia JC, Hanenberg H, Guenechea G, Bueren JA, Río P. Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum Gene Ther. 2010 May;21(5):623-30. doi: 10.1089/hum.2009.141.</citation>
    <PMID>20001454</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</investigator_affiliation>
    <investigator_full_name>Julian Sevilla</investigator_full_name>
    <investigator_title>M.D.PhD Specialist in Hematology Hemotherapy, Responsible for the Transfusion Service and Unit for the Obtention and Processing of Hematopoietic Progenitors and other cellular therapies at the Hospital Infantil Universitario Niño Jesús de Madrid.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

